http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003235875-A1

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-80
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56911
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
filingDate 2002-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2472210117a30ba4ab96e09c03a3a52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e806bc3801d1996fffe8ae20c00cd1c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_183eb7f2d8887356a36533212b9e321f
publicationDate 2003-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2003235875-A1
titleOfInvention Test for lyme disease
abstract The present invention provides a rapid and accurate method to identify the Borrelia burgdorferi (Bb) antigen, the cause of Lyme Disease, in a sample of whole blood, body tissues and fluids of a subject, a human or animal subject. The qualitative method provides a quick, easy and accurate method of detection of the Bb antigen. The quantitative method allows for monitoring of treatment in conjunction with severity of clinical signs and symptoms.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020194003-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020243159-A3
priorityDate 2002-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16850
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406705

Total number of triples: 20.